Oluyemi Okupe Sells 4,213 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 4,213 shares of Hims & Hers Health stock in a transaction that occurred on Thursday, December 26th. The stock was sold at an average price of $29.98, for a total value of $126,305.74. Following the completion of the sale, the chief financial officer now owns 128,365 shares in the company, valued at approximately $3,848,382.70. This represents a 3.18 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Oluyemi Okupe also recently made the following trade(s):

• On Friday, December 20th, Oluyemi Okupe sold 18,959 shares of Hims & Hers Health stock. The shares were sold at an average price of $25.77, for a total transaction of $488,573.43.
• On Monday, November 25th, Oluyemi Okupe sold 101,993 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.62, for a total transaction of $3,021,032.66.
• On Wednesday, November 13th, Oluyemi Okupe sold 142,886 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.93, for a total transaction of $4,276,577.98.
• On Monday, October 14th, Oluyemi Okupe sold 269,739 shares of Hims & Hers Health stock. The stock was sold at an average price of $20.31, for a total transaction of $5,478,399.09.
• On Monday, October 7th, Oluyemi Okupe sold 9,868 shares of Hims & Hers Health stock. The stock was sold at an average price of $19.96, for a total value of $196,965.28.

Hims & Hers Health Trading Down 6.8 %

NYSE:HIMS traded down $1.93 during mid-day trading on Friday, reaching $26.56. The company’s stock had a trading volume of 8,844,547 shares, compared to its average volume of 10,054,175. The firm’s fifty day moving average price is $26.29 and its two-hundred day moving average price is $21.46. The stock has a market cap of $5.80 billion, a P/E ratio of 60.37 and a beta of 1.25. Hims & Hers Health, Inc. has a 12-month low of $8.09 and a 12-month high of $35.02.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company had revenue of $401.56 million for the quarter, compared to the consensus estimate of $382.20 million. During the same quarter in the prior year, the firm earned ($0.04) earnings per share. The firm’s revenue for the quarter was up 77.1% compared to the same quarter last year. Analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on HIMS. Canaccord Genuity Group lifted their price target on Hims & Hers Health from $28.00 to $38.00 and gave the company a “buy” rating in a research report on Monday, December 2nd. Morgan Stanley initiated coverage on shares of Hims & Hers Health in a report on Tuesday, December 17th. They set an “overweight” rating and a $42.00 target price on the stock. Deutsche Bank Aktiengesellschaft increased their price target on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research note on Wednesday, November 6th. Bank of America cut shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and cut their price objective for the stock from $32.00 to $18.00 in a report on Thursday, November 14th. Finally, Piper Sandler reiterated a “neutral” rating and set a $21.00 target price (up from $18.00) on shares of Hims & Hers Health in a report on Tuesday, November 5th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, Hims & Hers Health presently has a consensus rating of “Hold” and an average price target of $22.80.

Hedge Funds Weigh In On Hims & Hers Health

A number of institutional investors and hedge funds have recently modified their holdings of HIMS. Renaissance Technologies LLC boosted its position in Hims & Hers Health by 113.1% in the second quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock worth $121,936,000 after purchasing an additional 3,205,108 shares during the last quarter. Wellington Management Group LLP boosted its holdings in shares of Hims & Hers Health by 34.5% in the third quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company’s stock worth $63,446,000 after buying an additional 883,230 shares during the last quarter. Geode Capital Management LLC grew its position in Hims & Hers Health by 12.7% during the third quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company’s stock valued at $79,029,000 after buying an additional 482,177 shares during the period. Healthcare of Ontario Pension Plan Trust Fund increased its holdings in Hims & Hers Health by 164.1% during the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 528,142 shares of the company’s stock valued at $10,663,000 after buying an additional 328,142 shares during the last quarter. Finally, Carnegie Investment Counsel bought a new position in Hims & Hers Health in the third quarter worth approximately $5,531,000. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.